Diagnostic value of ferritin for the severity of dengue infection in children

Retracted by the Editor-In-Chie

Diagnostic value of ferritin for the severity of dengue infection in children

Retracted by the Editor-In-Chie

Effect of Dissolved Oxygen Content on Photocatalytic Performance of Graphene Oxide

Graphene, a two-dimensional (2D) promising emergent photocatalyst consisting of earth-abundant elements. This study evaluated the potential of graphene oxide (GO) towards photocatalytic degradation of a novel organic dye, Methylene Blue (MB). In this work, photocatalytic activity of graphene oxide (GO), graphene oxide (GO) along with hydrogen peroxide (H2O2) were tested by photodegrading Methylene Blue (MB) in aqueous solution. The resulted GO nanoparticles were characterized by X-ray powder diffraction, Scanning Electron Microscopy, Energy Dispersive Spectroscopy and Fourier Transform Infrared Ray Spectroscopy. The XRD data confirms the sharp peak centered at 2Theta=10.44 degree corresponding to (002) reflection of GO. Based on our results, it was found that the resulted GO nanoparticles along with H2O2 achieved ~92% photodecolorization of MB compared to ~63% for H2O2 under natural sunlight irradiation at pH~7 in 60 min. The influences of oxygen and hydrogen peroxide (H2O2) on the degradation of MB during sunlight/GO process were investigated. Experimental results indicated that oxygen was a determining parameter for promoting the photocatalytic degradation. The rate constant of degradation (k1) increased from 0.019 to 0.042 per minute for dissolved oxygen content (DOC) 3.5 mg/L when direct photocatalysis (MB/GO) and H2O2-assisted photocatalysis (MB/H2O2/GO) were used. Owing to the fact that H2O2 acted as an electron and hydroxyl radicals scavenger, the addition of H2O2 should in a proper dosage to enhance the degradation of MB. Moreover, as the initial concentration of dissolved oxygen (DO) was increased from 2.8 to 3.9 mg/L, the rate constant of degradation (k1) increased from 0.035 to 0.062 per minute. The mechanism of photodegradation and kinetics were also studied for both direct photocatalysis and H2O2-assisted photocatalysis.Comment: In total 22 pages, total no. of figures 8, total no. of tables 6. arXiv admin note: text overlap with arXiv:1806.0648

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

Background Post-partum haemorrhage is the leading cause of maternal death worldwide. Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients. We aimed to assess the effects of early administration of tranexamic acid on death, hysterectomy, and other relevant outcomes in women with post-partum haemorrhage. Methods In this randomised, double-blind, placebo-controlled trial, we recruited women aged 16 years and older with a clinical diagnosis of post-partum haemorrhage after a vaginal birth or caesarean section from 193 hospitals in 21 countries. We randomly assigned women to receive either 1 g intravenous tranexamic acid or matching placebo in addition to usual care. If bleeding continued after 30 min, or stopped and restarted within 24 h of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given. Patients were assigned by selection of a numbered treatment pack from a box containing eight numbered packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to allocation. We originally planned to enrol 15 000 women with a composite primary endpoint of death from all-causes or hysterectomy within 42 days of giving birth. However, during the trial it became apparent that the decision to conduct a hysterectomy was often made at the same time as randomisation. Although tranexamic acid could influence the risk of death in these cases, it could not affect the risk of hysterectomy. We therefore increased the sample size from 15 000 to 20 000 women in order to estimate the effect of tranexamic acid on the risk of death from post-partum haemorrhage. All analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN76912190 (Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; and PACTR201007000192283. Findings Between March, 2010, and April, 2016, 20 060 women were enrolled and randomly assigned to receive tranexamic acid (n=10 051) or placebo (n=10 009), of whom 10 036 and 9985, respectively, were included in the analysis. Death due to bleeding was significantly reduced in women given tranexamic acid (155 [1·5%] of 10 036 patients vs 191 [1·9%] of 9985 in the placebo group, risk ratio [RR] 0·81, 95% CI 0·65–1·00; p=0·045), especially in women given treatment within 3 h of giving birth (89 [1·2%] in the tranexamic acid group vs 127 [1·7%] in the placebo group, RR 0·69, 95% CI 0·52–0·91; p=0·008). All other causes of death did not differ significantly by group. Hysterectomy was not reduced with tranexamic acid (358 [3·6%] patients in the tranexamic acid group vs 351 [3·5%] in the placebo group, RR 1·02, 95% CI 0·88–1·07; p=0·84). The composite primary endpoint of death from all causes or hysterectomy was not reduced with tranexamic acid (534 [5·3%] deaths or hysterectomies in the tranexamic acid group vs 546 [5·5%] in the placebo group, RR 0·97, 95% CI 0·87-1·09; p=0·65). Adverse events (including thromboembolic events) did not differ significantly in the tranexamic acid versus placebo group. Interpretation Tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible after bleeding onset. Funding London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation

Use of recombinant activated factor VII for massive postpartum hemorrhage

Objective. We hypothesised that patients with massive postpartum hemorrhage (PPH), defined as blood loss >1,500 ml, may benefit from the use of activated recombinant factor VII (rFVIIa). Design. Retrospective cohort study. Setting. Department of Obstetrics & Gynaecology, Dow University of Health Sciences. Population. Thirty-four women with a diagnosis of massive PPH. Methods. All patients with PPH who were admitted to the Department of Obstetrics & Gynecology and Surgical Intensive Care Unit of Civil Hospital Karachi, Pakistan, were included in the study. From March 2005 to October 2006, 34 patients fulfilled the criteria of massive PPH, of which 18 received rFVIIa to control bleeding, and 16 patients did not. Availability and cost of rFVIIa were the factors in drug allocation. Main outcome measures. Maternal mortality, correction of coagulopathy, the amount of blood products transfused and preservation of fertility. Results. Patients receiving rFVIIa had lower maternal mortality (5/18, 28% versus 8/16, 50%, OR: 0.04 (0.002, 0.83)), and received a lower number of packed red cell transfusions (4.0±4.46 versus 9.61±6.7, p value 0.007), against the comparison group. Patients receiving rFVIIa had lower activated partial thromboplastin (median: 13.0; 25-75th percentile: −25.0, −8.0, signed rank p<0.0001), and lower prothrombin times (median: −8.8; 25-75th percentile: −24.2, −4.8), after administration of drug. There was no significant difference in the rate of hysterectomy between the 2 groups (11/18 (61%) versus 6/16 (38%)). No adverse event attributable to rFVIIa was observed in the study. Conclusion. Activated recombinant factor VII can be a life-saving drug in patients with massive PPH